Status:
COMPLETED
The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
Fund for Scientific Research, Flanders, Belgium
Funds for Research in Ophthalmology, Belgium
Conditions:
Fuchs' Endothelial Dystrophy
Eligibility:
All Genders
Brief Summary
The purpose of this study is to gain further insights into the molecular pathogenesis of Fuchs' endothelial corneal dystrophy (FECD), to identify targets for potential specific drug therapy.
Eligibility Criteria
Inclusion
- FECD
- normal corneas (including enucleations for uveal melanoma)
- non-FECD oedematous corneas
Exclusion
- prior irradiation therapy for uveal melanoma
- corneal extension of uveal melanoma
Key Trial Info
Start Date :
October 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 13 2017
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT01795001
Start Date
October 1 2012
End Date
September 13 2017
Last Update
May 24 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Translational Cell and Tissue Research - campus Sint-Raf - UZ Leuven
Leuven, Belgium, 3000